Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Liabilities (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 9 years of Other Non-Current Liabilities data on file, last reported at $34.0 million in Q2 2026.

• Quarterly Other Non-Current Liabilities rose 267.29% year-over-year to $34.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $34.0 million (up 267.29% YoY) and the FY2025 annual result came in at $18.5 million, up 916.02% from the prior year.
• Other Non-Current Liabilities advanced to $34.0 million in Q2 2026, from $25.3 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $34.0 million in Q2 2026 to a low of $260000.0 in Q2 2022.
• A 5-year average of $7.0 million and a median of $1.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 77.21% — and 2025, when it jumped 916.02%.
• Tracing KNSA's Other Non-Current Liabilities over 5 years: stood at $1.8 million in 2022, then gained by 1.03% to $1.9 million in 2023, then retreated by 1.88% to $1.8 million in 2024, then jumped by 916.02% to $18.5 million in 2025, then surged by 83.66% to $34.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $34.0 million (Q2 2026), $25.3 million (Q1 2026), and $18.5 million (Q4 2025), per Business Quant data.